PrOtamIne doSing clOt imagiNg (POISON) Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

20 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-05-08

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The proposed study involves using two different high-resolution microscopic imaging techniques to examine the health and platelet invasion of clot in patients who were given 1:1 protamine / heparin and compare this to clot from patients who had heparin reversed using the PRODOSE algorithm. Patients will be treated according to the routine clinical practice of their individual care team.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT Pilot)

NCT00182364

Critically Ill Deep Venous Thrombosis

COMPLETED PHASE3

Targeted Metabolic Profiling in Deep Vein Thrombosis

NCT04096755

Deep Vein Thrombosis

UNKNOWN

Treatment for Blood Clots in the Veins of the Legs

NCT00001713

Embolism Thrombophlebitis

COMPLETED PHASE1

Post-thrombotic Syndrome & Predictors of Recurrence in Catheter-related Thrombosis

NCT01999179

Venous Thrombosis Neoplasms

COMPLETED NA

Comparative Analysis of Injectable Anticoagulants for Thromboprophylaxis Post Cancer-related Surgery

NCT01444612

Thrombosis, Venous

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Sample collection at RPH

Patients will have a total of 14ml of blood taken during the procedure.

The first 7ml will be taken after induction of anaesthesia along with routine blood gas and coagulation sampling through the routinely indwelling arterial catheter. The initial sample must be taken before any heparin has been administered. This will be used to fill 2 x 3.5ml citrated (green top) blood tubes. These will be clearly labelled as "pre-heparin" with a Tissue Bank ID number.

The second 7ml will be taken 5 minutes after heparin has been reversed with protamine after cessation of cardiopulmonary bypass. It will again be taken at the same time as routine sampling for blood gas and coagulation studies. Analog to the first sample, it will again be divided and used to fill 2 x 3.5ml citrated (green top) blood tubes. These will be clearly labelled as "post-protamine" with the same ID number and whether "1:1" or a "PRODOSE algorithm determined" protamine: heparin ratio was used.

In keeping with clinical routine, ROTEM coagulation testing and full blood counts will be requested as seen necessary by the clinical team.

The samples will be sent to Royal Papworth Hospital (RPH) Tissue Bank for initial processing. Samples need to be processed within 4 hours of blood draw.

After initial processing, samples will be sent for confocal imaging to the MRC Laboratory of Molecular Biology (LMB) and for SEM imaging to the University of Oxford respectively.

Clinical data to be collected (to be completed by anaesthetic team).

1. Demographic information: Age / Gender / Weight / Height / Medication history;
2. Type of surgery;
3. Cardiac drug history and antiplatelets / anticoagulants and timing;
4. Coagulation tests (ACT / ROTEM) at the following points: a) Pre-heparin, b) Post-heparin, pre-CPB, c) Throughout CPB, c) Post-protamine;
5. Full blood count at the following points: a) Pre-surgery and date of sample, b) Post-protamine; 6) CPB and x-clamp times, nadir temperature

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiac Surgery

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Standard

10 patients receiving standard reversal with 1:1 protamine / heparin ratio

No interventions assigned to this group

PRODOSE Algorithm

10 patients who had heparin reversed using the PRODOSE algorithm anticipated (average protamine / heparin ratio 0.6:1).

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* undergoing elective, uncomplicated single procedure cardiac surgery with anticipated CPB duration \< 120 min
* with all anticoagulant drugs stopped at least 5 days before surgery, apart from aspirin
* with normal full blood count and clotting screen pre-OP.

Exclusion Criteria

* emergency surgery
* inability to stop anticoagulants except aspirin for 5 days pre-OP
* complex surgery with anticipated CPB duration \> 120min
* operations planned to be done at temperature on CPB \< 34 degrees
* operations requiring deep hypothermic circulatory arrest, solid organ transplantation
* know blood dyscrasia
* intra-operative blood or blood product transfusion or post-operative coagulopathy

Eligible Sex

ALL

Accepts Healthy Volunteers

No